Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
C.30.1NNIH-TH_NCCCCACTGCGTTCTCCATT1957.892837628358R-22126.5Thailand
C.30.1NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
C.30.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
C.30.1NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
C.30.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
C.30.1NCorman-NGAGGAACGAGAAGAGGCTTG20552883328814R-22527.5Germany
C.30.1NWon-NGTTGCGACTACGTGATGAGG20552884928830R-23088.1South Korea
C.30.1NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
C.30.1NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-20936.4Hong Kong
C.30.1NChan-NTTGGATCTTTGTCATCCAATTTG2334.782930629284R-21867.4China
C.30.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.30.1ORF1abNIID WH-1 F501R913CTTTACCAGCACGTGCTAGAAGG2352.17896874R-25657.5Japan
C.30.1ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-17929.7Japan
C.30.1ORF1abNIID WH-1 Seq F519R840GACATAGCGAGTGTATGCC1952.63823805R-20165.2Japan
C.30.1SWuhanCoV-spk1TGTGGTTCATAAAAATTCCTTTGTG25322490024876R-23857.7Japan
C.30.1SNIID WH-1 F24381R24873ATTTGAAACAAAGACACCTTCAC2334.782485624834R-22193.2Japan
C.30.1SNIID WH-1 Seq F24383R24865CAAAGACACCTTCACGAGG1952.632484824830R-20677.6Japan
B.1.177.76ORF1abYip-ORF1abTTGTTATAGCGGCCTTCTGT204519701951R-21075.5China
B.1.177.76ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.177.76ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
B.1.177.76ORF1abCN-CDC-ORF1abACGATTGTGCATCAGCTGA1947.371346013442R-20306.2China
B.1.177.76ORF1abYoung-ORF1abCACTTAATGTAAGGCTTTGTTAAG2433.331424314220R-22408Singapore
B.1.177.76ORF1abCharité-ORF1bCARATGTTAAASACACTATTAGCATA2623.081553015505R-9191.15Germany
B.1.177.76ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
B.1.177.76ORF1abChan-ORF1abGTGTGATGTTGAWATGACATGGTC2441.671635316330R-13317.5China
B.1.177.76ORF1abHKU-ORF1bAACRCGCTTAACAAAGCACTC2142.861890918889R-17655.9Hong Kong
B.1.177.76SYoung-SATCCAGCCTCTTATTATGTTAGAC2437.52187621853R-22070.7Singapore
B.1.177.76SChan-SCAAGCTATAACGCAGCCTGTA2147.622286922849R-22073.5China
B.1.177.76SWon-SCACCTGTGCCTGTTAAACCA20502321323194R-21965.9South Korea
B.1.177.76EWon-ECACACAATCGATGCGCAGTA20502636526346R-19261.4South Korea
B.1.177.76ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
B.1.177.76EHuang-EGCAGCAGTACGCACACAATC20552637626357R-23540.5China
B.1.177.76ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.177.76NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
B.1.177.76NNIH-TH_NCCCCACTGCGTTCTCCATT1957.892837628358R-22126.5Thailand
B.1.177.76NUS-CDC-N-1TCTGGTTACTGCCAGTTGAATCTG2445.832835828335R-25148.4US
B.1.177.76NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.76NUS-CDC-N-3TGTAGCACGATTGCAGCATTG2147.622875228732R-23779.6US
B.1.177.76NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.76NCorman-NGAGGAACGAGAAGAGGCTTG20552883328814R-22527.5Germany
B.1.177.76NWon-NGTTGCGACTACGTGATGAGG20552884928830R-23088.1South Korea
B.1.177.76NNIID-JP-NTGGCAGCTGTGTAGGTCAAC20552928229263R-20522.3Japan
B.1.177.76NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-20936.4Hong Kong
B.1.177.76NChan-NTTGGATCTTTGTCATCCAATTTG2334.782930629284R-21867.4China
B.1.177.76NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.76ORF1abNIID WH-1 F501R913CTTTACCAGCACGTGCTAGAAGG2352.17896874R-25657.5Japan
B.1.177.76ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
B.1.177.76ORF1abNIID WH-1 Seq F519R840GACATAGCGAGTGTATGCC1952.63823805R-20165.2Japan
B.1.177.76SWuhanCoV-spk1TGTGGTTCATAAAAATTCCTTTGTG25322490024876R-23857.7Japan
B.1.177.76SNIID WH-1 F24381R24873ATTTGAAACAAAGACACCTTCAC2334.782485624834R-22193.2Japan
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used